Proton Intelligence, a Canada-based company developing a continuous potassium monitoring (CKM) platform, has closed a $6.95m seed financing round.
Investors in the seed round were SOSV, Tenmile, LongeVC, We Venture Capital, 15th Rock, Trampoline Venture Partners, and Exor.
Proton Intelligence will use the funds to start human trials for potassium monitoring in patients with kidney disease.
Its CKM platform is designed to advance the management of cardio-kidney-metabolic diseases by delivering real-time, on-demand potassium-level data to clinicians and patients. This could help ensure the safe implementation of optimal medical therapies.
We Venture Capital head Louise Warme said: “We Venture Capital have been impressed by this true breakthrough in electrolyte sensing capability, which will fulfil a critical gap in the current care continuum for many patients at risk from dyskalemia.
“We look forward to working with the Proton Intelligence team on the next phase of their journey.”
According to Proton Intelligence, potassium is a key biomarker for cardio-kidney-metabolic diseases, but is difficult to measure. Dangerous fluctuations in potassium can lead to serious cardiac arrhythmias and sudden death.
The lack of timely potassium measurements prevents patients from receiving the correct life-saving treatments.
Proton Intelligence’s CKM platform enables continuous, accurate potassium monitoring, empowering healthcare providers to treat patients with kidney disease or heart failure better.
The monitoring technology developer has launched clinical studies to evaluate the performance of its CKM platform in individuals with severely impaired kidney function, including those with end-stage renal disease (ESRD) and chronic kidney disease (CKD).
Proton Intelligence founder and CEO Sahan Ranamukhaarachchi said: “This fundraising milestone represents a major leap forward for us.
“We are immensely grateful for the trust and support of our investors, who share our vision of revolutionising cardio-kidney-metabolic care.
“Their belief in our mission sees us funded through a number of clinical feasibility trials ahead of a pivotal study planned for 2026 and get closer to making CKM a reality for millions of patients.”
